Alzheimer’s disease remains one of the most complex and devastating neurodegenerative disorders, affecting over 55 million people globally. With projections estimating this number will rise to 139 million by 2050, the urgency to develop effective treatments has never been greater. Historically, AD drug development has been marked by setbacks and limited therapeutic success due to…
Revitalizing the brain’s ‘housekeepers’ to combat Alzheimer’s
A potential new strategy against Alzheimer’s disease is taking shape in the brain’s own defense system. By boosting a specific enzyme in the brain’s immune cells, researchers at Cedars-Sinai have dramatically reduced the hallmark plaques of Alzheimer’s and reversed cognitive decline in mice. The news opens the door to potential cellular therapies for a disease…
Phase 3 trial shows donanemab reduces Alzheimer’s symptoms by 35%
According to results from the Phase 3 TRAILBLAZER-ALZ 2 study published in JAMA, the monoclonal antibody donanemab significantly slowed cognitive and functional decline in patients with early symptomatic Alzheimer’s disease by approximately 35% at one year compared to placebo. The trial enrolled 1736 patients across 277 research centers in 8 countries. Another monoclonal antibody, Leqembi…
Donanemab slows cognitive decline in early Alzheimer’s patients by 35%
Lilly’s (NYSE:LLY) shares were up more than 5.36% to $425.88 after the company announced upbeat results from the phase 3 TRAILBLAZER-ALZ 2 study, which revealed that the experimental Alzheimer’s drug donanemab significantly slowed cognitive decline in patients with early symptomatic Alzheimer’s disease at 18 months. Almost half of patients, 47%, who received donanemab had no…